Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the Annual Meeting of Stockholders held by Seres Therapeutics, Inc. on June 26, 2018. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
A total of 38,498,469 shares were present at the meeting, representing approximately 94.7% of outstanding common stock as of the April 27, 2018 record date. The following proposals were approved:
- Election of Directors (Item 1): Three Class III directors were elected to serve until the 2021 Annual Meeting.
- Ratification of Auditors (Item 2): The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2018, was ratified.
Director Election Details
| Nominee | Votes FOR | Votes WITHHELD | Broker Non-Votes |
|---|---|---|---|
| Noubar B. Afeyan, Ph.D. | 31,689,669 | 1,348,844 | 5,459,956 |
| Grégory Behar | 32,022,317 | 1,016,196 | 5,459,956 |
| Kurt C. Graves | 23,192,033 | 9,846,480 | 5,459,956 |
Auditor Ratification Details
| Category | Count |
|---|---|
| Votes FOR | 38,446,403 |
| Votes AGAINST | 48,636 |
| Votes ABSTAINED | 3,430 |
| Broker Non-Votes | 0 |
Outlook, Risks, and Management Commentary
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly reports the outcome of the shareholder vote.
Key Facts for Investor Verification
- Verify the high level of shareholder participation (94.7%) at the annual meeting.
- Note the significant number of votes withheld for director Kurt C. Graves (9,846,480) compared to the other nominees.
- Confirm the ratification of PricewaterhouseCoopers LLP as the auditor for the 2018 fiscal year.
- Review the Definitive Proxy Statement filed on April 30, 2018, for detailed background on the director nominees and proposals.